ALK and non-small cell lung carcinoma: It has recently been shown that identification of NSCLC patients by detection of genetic aberrations, specifically EGFR-activating mutations and the EML4-ALK fusion gene, allows for better prediction of response to EGFR tyrosine kinase inhibitors and ALK inhibitors, respectively [1], [2].